Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial cancer

Bookmark and Share
Published: 14 Sep 2022
Views: 25
Prof Jonathan E Rosenberg - Memorial Sloan Kettering Cancer Center, New York City, USA

Prof Jonathan E Rosenberg speaks to ecancer about a study investigating the potential for enfortumab vedotin combined with pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer

The primary endpoint was confirmed objective response rate per RECIST v1.1 by blinded independent central review. Secondary endpoints included duration of response and safety.

Enfortumab vedotin plus pembrolizumab showed high overall response rate with rapid responses and median duartion of response not reached in a first-line cisplatin-ineligible population. 

The safety profile was tolerable and generally consistent with the known profile for enfortumab vedotin plus pembrolizumab. Enfortumab vedotin monotherapy was consistent with prior experience.  

These data support ongoing investigations of first line enfortumab vedotin + pembrolizumab in patients with locally advance or metastatic urothelial cancer who have a high unmet need.